



## **Aravax appoints Annette Leahy as Director of Clinical Operations**

**21 July 2023, Melbourne, Australia:** Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies which are safe, convenient, and precisely targeted, today announces the appointment of Annette Leahy as Director of Clinical Operations.

Annette brings 20 years of clinical research experience in operational and project management roles across biotechnology, pharmaceutical, and contract research organisations. Her expertise will be an asset for Aravax as it proceeds through Phase 2 trials in Australia and the United States, and prepares for larger Phase 3 trials.

“We are thrilled that Annette has joined our team at this exciting time. She is a skilled clinical research leader and her experience across world-leading companies will be valuable as Aravax progresses the development of PVX108 and progresses to trials in international markets,” says Dr. Pascal Hickey, CEO of Aravax.

Aravax recently completed a successful Phase 1 trial for PVX108 and a Phase 2 clinical study is now underway.

Annette says, “I am thrilled to be joining the talented Aravax team and look forward to supporting the ongoing advancement of PVX108. A groundbreaking treatment with the potential to deliver major clinical benefits to people suffering with peanut allergies.”

Before joining Aravax, Annette was the Director of Clinical Research at Opthea, a Melbourne-based company developing novel therapies to treat highly prevalent and progressive retinal diseases, where she oversaw multinational Phase 2 and 3 clinical trials.

Annette has extensive project management experience. At Biota where she led a global influenza clinical trials program under a US government contract, and at Nucleus Network, where she managed early phase clinical studies in a Phase 1 unit.

She also held senior leadership roles at Swisse Wellness and Novotech, where she developed and oversaw clinical trial teams and departments and holds a Bachelor of Health Information Management from La Trobe University.

**ENDS**

### **About Aravax**

Aravax is a clinical stage biotechnology company focused on revolutionising the treatment of food allergies with next-generation specific immunotherapies which are safe, effective and convenient. Aravax applies proprietary technology and know-how to design highly targeted pharmacotherapies, which reset the immune system to tolerate a specific allergen without evoking allergic reactions during treatment. The lead product, PVX108, is being developed for the treatment of peanut allergy. Aravax is headquartered in Melbourne, Australia, and was founded in 2015 with venture capital from Brandon Capital and technology from Alfred Health and Monash University.

For more information visit: [www.aravax.com.au](http://www.aravax.com.au)